These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 19934279)

  • 21. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
    Pan BS; Chan GK; Chenard M; Chi A; Davis LJ; Deshmukh SV; Gibbs JB; Gil S; Hang G; Hatch H; Jewell JP; Kariv I; Katz JD; Kunii K; Lu W; Lutterbach BA; Paweletz CP; Qu X; Reilly JF; Szewczak AA; Zeng Q; Kohl NE; Dinsmore CJ
    Cancer Res; 2010 Feb; 70(4):1524-33. PubMed ID: 20145145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor.
    Mohyeldin MM; Akl MR; Ebrahim HY; Dragoi AM; Dykes S; Cardelli JA; El Sayed KA
    Oncotarget; 2016 May; 7(22):32247-73. PubMed ID: 27086914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.
    Liu Z; Galemmo RA; Fraser KB; Moehle MS; Sen S; Volpicelli-Daley LA; DeLucas LJ; Ross LJ; Valiyaveettil J; Moukha-Chafiq O; Pathak AK; Ananthan S; Kezar H; White EL; Gupta V; Maddry JA; Suto MJ; West AB
    J Biol Chem; 2014 Nov; 289(47):32937-51. PubMed ID: 25228699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.
    Munshi N; Jeay S; Li Y; Chen CR; France DS; Ashwell MA; Hill J; Moussa MM; Leggett DS; Li CJ
    Mol Cancer Ther; 2010 Jun; 9(6):1544-53. PubMed ID: 20484018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3.
    Liu X; Wang Q; Yang G; Marando C; Koblish HK; Hall LM; Fridman JS; Behshad E; Wynn R; Li Y; Boer J; Diamond S; He C; Xu M; Zhuo J; Yao W; Newton RC; Scherle PA
    Clin Cancer Res; 2011 Nov; 17(22):7127-38. PubMed ID: 21918175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and synthesis of triazolopyridazines substituted with methylisoquinolinone as selective c-Met kinase inhibitors.
    Ryu JW; Han SY; Yun JI; Choi SU; Jung H; Ha JD; Cho SY; Lee CO; Kang NS; Koh JS; Kim HR; Lee J
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7185-8. PubMed ID: 22001029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models.
    Ai J; Chen Y; Peng X; Ji Y; Xi Y; Shen Y; Yang X; Su Y; Sun Y; Gao Y; Ma Y; Xiong B; Shen J; Ding J; Geng M
    Mol Cancer Ther; 2018 Apr; 17(4):751-762. PubMed ID: 29237805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
    Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
    Ji F; Liu X; Wu Y; Fang X; Huang G
    Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase.
    Albrecht BK; Harmange JC; Bauer D; Berry L; Bode C; Boezio AA; Chen A; Choquette D; Dussault I; Fridrich C; Hirai S; Hoffman D; Larrow JF; Kaplan-Lefko P; Lin J; Lohman J; Long AM; Moriguchi J; O'Connor A; Potashman MH; Reese M; Rex K; Siegmund A; Shah K; Shimanovich R; Springer SK; Teffera Y; Yang Y; Zhang Y; Bellon SF
    J Med Chem; 2008 May; 51(10):2879-82. PubMed ID: 18426196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met.
    Northrup AB; Katcher MH; Altman MD; Chenard M; Daniels MH; Deshmukh SV; Falcone D; Guerin DJ; Hatch H; Li C; Lu W; Lutterbach B; Allison TJ; Patel SB; Reilly JF; Reutershan M; Rickert KW; Rosenstein C; Soisson SM; Szewczak AA; Walker D; Wilson K; Young JR; Pan BS; Dinsmore CJ
    J Med Chem; 2013 Mar; 56(6):2294-310. PubMed ID: 23379595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
    Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
    Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile.
    Fujita H; Miyadera K; Kato M; Fujioka Y; Ochiiwa H; Huang J; Ito K; Aoyagi Y; Takenaka T; Suzuki T; Ito S; Hashimoto A; Suefuji T; Egami K; Kazuno H; Suda Y; Nishio K; Yonekura K
    Mol Cancer Ther; 2013 Dec; 12(12):2685-96. PubMed ID: 24140932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors.
    Dorsch D; Schadt O; Stieber F; Meyring M; Grädler U; Bladt F; Friese-Hamim M; Knühl C; Pehl U; Blaukat A
    Bioorg Med Chem Lett; 2015 Apr; 25(7):1597-602. PubMed ID: 25736998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.
    Zou HY; Li Q; Lee JH; Arango ME; McDonnell SR; Yamazaki S; Koudriakova TB; Alton G; Cui JJ; Kung PP; Nambu MD; Los G; Bender SL; Mroczkowski B; Christensen JG
    Cancer Res; 2007 May; 67(9):4408-17. PubMed ID: 17483355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. O-linked triazolotriazines: potent and selective c-Met inhibitors.
    Chen F; Wang Y; Ai J; Zhan Z; Lv Y; Liang Z; Luo C; Mei D; Geng M; Duan W
    ChemMedChem; 2012 Jul; 7(7):1276-85. PubMed ID: 22539497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as novel, potent and selective c-Met kinase inhibitors: Synthesis, SAR study, and biological activity.
    Zhang L; Zhao J; Zhang B; Lu T; Chen Y
    Eur J Med Chem; 2018 Apr; 150():809-816. PubMed ID: 29602036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo.
    Han SY; Lee CO; Ahn SH; Lee MO; Kang SY; Cha HJ; Cho SY; Ha JD; Ryu JW; Jung H; Kim HR; Koh JS; Lee J
    Invest New Drugs; 2012 Apr; 30(2):518-23. PubMed ID: 21080208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors.
    Cepero V; Sierra JR; Corso S; Ghiso E; Casorzo L; Perera T; Comoglio PM; Giordano S
    Cancer Res; 2010 Oct; 70(19):7580-90. PubMed ID: 20841479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.